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Background. In this study, using a murine model of 
aortic allotransplantation, the role of blockade of sig-
naling through CD281B7 and CD40/CD40 ligand co-
stimulatory pathways in the evolvement of posttrans-
plant vasculopathy was examined. 
Methods. Aortic allografts were transplanted across 
C57BUIOJ (H2b )-C3H (H2k) strain combinations. 
Transient or more stable blockade of second signaling 
was achieved by either a single injection or multiple 
injections of CTLA4-Ig fusion protein (200 ILgldose i.p.) 
and/or anti-CD40 ligand (CD40L) monoclonal antibody 
(250 ILg i.m.). At day 30 after transplantation, the grafts 
were harvested for histopathological and immunohis-
tochemical examination. 
Results. Similar to allografts of untreated animals, 
aortic allografts obtained from recipients treated with 
either CTLA4-Ig or anti-CD40L monoclonal antibody 
alone exhibited marked narrowing of the lumen pri-
marily due to concentric intimal thickening caused by 
proliferation of a-smooth muscle actin-positive cells. 
Contemporaneous treatment, however, with either a 
single injection or multiple injections of CTLA4-Ig and 
anti-CD40L monoclonal antibody resulted in marked 
diminution of intimal thickening. Interestingly, con-
current prolonged inhibition of CD281B7 and CD401 
CD40L pathways resulted in complete abrogation of 
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the development of posttransplant arteriopathy. 
Conclusion. These data suggest that a more stable 
disruption of signaling through costimulatory path-
ways may be required to obviate the development of 
posttransplant vasculopathy. 
At the cellular interface, the costimulatory events that lead 
to optimal T-cell activation have been targeted for inhibition 
of this latter phenomenon (1,2). In the realm of allotrans-
plantation, the use of CTLA4-Ig fusion protein to block sig-
naling through the CD281B7 pathway has been shown to 
enhance allograft survival (3-5) and to prevent or reduce the 
changes due to chronic rejection (CR*) (3-6). 
The recent demonstration of the expression of gp39 (CD40 
ligand [CD40LJ) on activated T cells and its function as a 
ligand for CD40 expressed on various antigen-presenting 
cells has unveiled another dominant costimulatory pathway 
for T- and B-cell activation (7). The role of signaling through 
the CD40/CD40L pathway in mediating acute allograft rejec-
tion in a fully disparate murine model of heterotopic cardiac 
transplantation has been documented (8, 9). Furthermore. 
similar to that of CD281B7, a transient blockade of CD40/ 
gp39 pathway by the use of monoclonal antibody (mAb) di-
rected against the ligand for CD40 (MR-l) has been shown to 
enhance allograft survival (8, 9) but with minimal beneficial 
effect on posttransplant arteriopathy (10). Interestingly, the 
simultaneous blockage of signaling through the CD281B7 and 
CD40/CD40L pathways by the contemporaneous use of 
CTLA4-Ig and MR-l resulted not only in prolongation of skin 
and heart allograft survival but complete abrogation of the 
changes pathognomonic of CR in a vascularized model o! 
heart allotransplantation (10). 
Recognizing the importance of allogeneic immune re-
sponses in the etiopathology ofCR, we have made an attempt 
to delineate the role of costimulatory molecules in the evolve-
ment of posttransplant vasculopathy. For this purpose. in-
~ Abbreviations: ,,-smA -. a-smooth muscle actin·positive cells: 
AO. aorta; AOTx. aortic transplantation; CD40L. CD40 ligand; CR. 
chronic rejection; mAb. monoclonal antibody. 
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bred 6- to lO-week-old male C57BUI0J <BI0; H2b ) and C3H 
(H2k) mice obtained from Jackson Laboratory <Bar Harbor, 
ME) were maintained in a specific pathogen-free facility with 
Purina rodent chow and tap water provided ad libitum and 
used at 10-12 weeks of age. Anti-CD40L (gp39; MR-ll, a 
hamster mAb specific for murine gp39. was purchased from 
TSD Bioservice (Newark, DE). The human CTLA4-Ig fusion 
protein, which contains the extracellular domain of human 
CTLA4 and an immunoglobulin Cy chain, was generously 
provided as a gift by Peter Linsley <Bristol-Myers Squibb, 
Inc., Seattle, WA). Isotype-matched control human IgG (L6) 
and hamster IgG were purchased from Jackson ImmunoRe-
search Laboratories, Inc. (West Grove, PAl. For detection of 
a-smooth muscle actin-positive (a-smA +) cells, mouse a-hu-
man mAb (IgG2a ) was purchased from DAKO Corp. (Carpin-
teria, CAl. Biotinylated horse a-mouse IgG was purchased 
from Vector Laboratories, Inc. <Burlingame, CAl. The ABC 
immunoperoxidase staining kit (VECTASTIN) was obtained 
from Vector. The chromogen 3-amino-9-ethylcarbazol was 
acquired from ScyTek Laboratories, Inc. (Logan, UT). 
With inhalation anesthesia using methoxyflurane (Meto-
fane; Pitman-Moore, Inc., Mundelein, IL) and with the aid of 
a dissection microscope, aortic transplantation (AOTx) was 
performed (1). Briefly, a 6- to 9-mm segment of the descend-
ing part of the donor's thoracic aorta (AO) was harvested and 
anastomosed (end to side) to the recipient's abdominal AO. 
The native abdominal AO was then ligated and severed, 
thereby converting an end-to-side anastomosis to a quasi-
end-to-end anastomosis. The recipients (C3H) of aortic al-
lografts from BI0 donors were divided into eight groups (Fig. 
1). CTLA4-Ig fusion protein was used at a dose of 200 ILg i.p. 
and anti-gp39 (MR-l) at 250 ILg i.m. Each group comprised 
five to seven animals. Group A was untreated. In group B, 
animals were given a single dose of isotype-matched human 
IgG (L6, 200 ILg i.p.) and hamster IgG (250 ILg i.m.) on day 2 
after transplantation. Group C animals were given a single 
injection of CTLA4-Ig on day 2 after transplantation. In 
group D, 10 doses of CTLA4-Ig were given starting on day 2 
after transplantation and every 72 hr thereafter. In group E, 
animals were given three doses of anti-gp39 on days 0, 2, and 
4 after transplantation. In group F, a single dose of both 
CTLA4-Ig and MR-l was given on day 2 after transplanta-
tion. In group G, animals were given three doses of both 
CTLA4-Ig and MR-l on days 0, 2, and 4 after transplanta-
tion. In group H, animals were given 10 doses of both 
CTLA4-Ig and anti-gp39 mAb starting on day 2 after trans-
plantation and every 72 hr thereafter. AOTx across un-
treated syngeneic (C3H-C3H) animals served as an addi-
tional control. Allografts were harvested on day 30 after 
transplantation, when distinctive changes of CR are most 
evident (2). 
At day 30 after AOTx, with the animals under anesthesia, 
the aortic allografts were retrieved, fixed for 48 to 72 hr in 
10% buffered formalin, and sectioned (4 J..Lm thick) using a 
microtome. In addition to hematoxylin and eosin staining 
(Surgipath, Richmond, IL), Verhoeff-van Gieson (elastic fi-
bers) and Masson's trichrome (collagen) staining was also 
performed. Additionally, the presence of a-smA + cells was 
determined using a previously described method (12). 
Briefly, after hydration, endogenous-peroxidase activity was 
blocked by treating the sections for 45 min with 0.6% solution 
containing 71% methanol, 24% dH20, and 5% H2 0 2 • After 
Group dO d2 
• • 
d30 , 
I. Controls 
A 
B 
810 ..... C3H 
aorta Tx 
, 
untreated 
Irrelevant Isotypes 
• 0 (2001-'9 i.p.l250"'9 Lm.) 
Harvest 
. , 
. , 
II. CTLA4-lg alone 
c 
CTLA4.19 
, 0 (200 "'9 i.p.) 
" 
CTLA4·19 (200 "'9 i.p.) 
from d2 and every 72h thereafter 
D ,'0 0 0 0 0 0 0 0 0 0 " 
III. anti-CD40L (MR1 mAb) alone 
E 
, 
" 
• • • MR1 (250 "'9 i.m.) 
dO,d2,d4 
IV. CTLA4-lg + anti-CD40L (MR1) 
F 
G 
H 
d2 
CTLA4.19 (200 1-'9 Lo.) 
• 
MR1 (250!l9 Lm.) 
CTLA4·lg (200 "'9 :.p.) 
dO,d2,d4 
. y y r 
~KKl 
MR1 (251J ~9 Lm.) 
dO.d2.d4 
CTLA4·lg (200 ~9 I.p.) 
from d2 and every 72h thereafter 
• 
."0 Q 0 y y Q y y y r " 
............ 
MR1 (250 I-'g i.m.) 
from d2 and every 72h thdreatter 
FIGURE 1. Schematic representation of various protocols used to 
treat BlO ..... C3H aortic allotransplant recipients with CTLA4-Ig fu-
sion protein and/or anti·CD40L mAb. Untreated recipients and those 
treated with the isotype-matched irrelevant mAb served as controls. 
For details see Materials and Methods. 
two washings, nonspecific binding was blocked by a 20-min 
incubation in Lipshaw Universal Protein Blocker and then a 
45-min incubation with mouse a-human mAb directed 
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FIGURE 2. Histopathological and immunohistochemical staining of AO obtained at day 30 after transplantation from BIO-C3H recipients 
receiving CTLA4-lg and/or MR-l. The hematoxylin and eosin-stained section of the native donor (BIO) AO exhibited normal morphology (Ab 
inset); staining for elastic fibers using Verhoetf-van Gieson's stain suggested that the internal elastic membrane was intact (A and Aa inset). 
Similar observations have also been made after hematoxylin and eosin staining of transplanted AO obtained from syngeneic (C3H-C3H) 
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against a-smA + cells; the sections were then washed two 
times with phosphate-buffered saline. Biotinylated horse 
a-mouse IgG was used to identify the primary antibody, and 
after two washings, the sections were incubated for 30 min 
with avidin-biotin complex (Vector). Coloration was devel-
oped using 3-amino-9-ethylcarbazol, and sections were 
washed twice with phosphate-buffered saline and then coun-
terstained with hematoxylin. 
As reported previously (11, 12), aortic allografts obtained 
at day 30 after transplantation from untreated recipients 
(group A) exhibited changes characteristic of CR (Fig, 2C). 
The diffuse intimal thickening, which involved the entire 
circumference of the vessel, was largely due to proliferation 
of a-smA + cells (Fig. 2C, inset). Patchy destruction of the 
internal elastic membrane was also distinct, as was the in-
timal deposition of fibrous tissue and collagen (Fig. 2C). In 
contrast, syngeneic aortic grafts ECPe~CPeF retained nor-
mal morphology (Fig. 2B) and were virtually indistinguish-
able from native AO grafts (Fig. 2A). Furthermore, the his-
topathological abnormalities observed in irrelevant isotype-
matched, mAb-treated C3H recipients of BI0 AO (Fig. I, 
group B) harvested at day 30 after transplantation (Fig. 2D) 
were very similar to those of allografts from untreated ani-
mals (Fig. 2C). 
Blockade of signaling through the CD281B7 pathway by 
administration of a single dose of CTLA4-Ig given at day 2 
after AOTx (Fig. I, group C) failed to abrogate the develop-
ment of CR (Fig. 2E). Concentric intimal thickening with 
disruption of internal elastic limiting membrane was evident 
in these aortas at day 30 after transplantation. The magni-
tude of these changes was comparable to changes witnessed 
in untreated recipients of AOTx (Fig. 2C) and in animals 
receiving irrelevant mAb (Fig. 2D). Of further importance is 
the observation that the morphology of the aortic allografts 
procured from recipients undergoing treatment with 10 con-
secutive doses of CTLA4-Ig (Fig. I, group D) was indistin-
guishable (Fig. 2F) from that of untreated animals (Fig. 2C) 
and animals treated with isotype-matched irrelevant mAb 
(Fig.2D). 
Since the transient or more stable blockage of the CD281B7 
pathway did not abrogate the development of CR, we pro-
ceeded to ascertain whether interruption of signaling 
through the CD40/CD40L pathway by the use of a-CD40L 
mAb (MR-l) alone (Fig. I, group E) would have any effect on 
posttransplant vasculopathy. Toward the achievement of this 
goal, three doses of MR-l were injected at days 2, 4, and 6 
after AOTx. Aortic allografts obtained at day 30 after trans-
plantation revealed the presence of intimal thickening with 
patchy destruction of internal elastic membrane (Fig. 2G). 
These changes were comparable to those observed in un-
treated animals (Fig. 2C) and in animals treated with either 
irrelevant mAb (Fig. 2D) or with CTLA4-Ig fusion protein 
(Fig. 2, E and F). 
Perioperative concomitant blockade of both the CD281B7 
and the CD40/CD40L pathways by the use of CTLA4-lg and 
MR-l, respectively, has previously been shown to prevent the 
development of CR in a vascularized heart model of allo-
transplantation in mice (10). To study the corollary of such a 
treatment on the evolvement of posttransplant arteriopathy 
in this model, we proceeded to block both costimulatory path-
ways by treating the aortic allograft recipients with a single 
dose of CTLA4-Ig and MR-l (Fig. I, group F). Unlike the 
results observed after discrete blockade of the costimulatory 
pathways, treatment with the latter protocol resulted in a 
marked decrease in intimal thickening (Fig. 3A, inset); this 
was in contrast to the diffuse and concentric thickening 
seen in aortic allografts of untreated animals (Fig. 2C) and 
in animals treated with irrelevant mAb (Fig. 2D). Despite 
diminution of intimal thickening, there was still some 
evidence of residual endothelial damage and minimal (al-
beit less than that observed in untreated allograft recipi-
ents) disruption of the internal elastic limiting membrane 
(Fig.3A). 
In contrast to previous reports (10), treatment with three 
consecutive doses ofCTLA4-Ig and MR-l (Fig. I, group G) did 
not result in complete abrogation of CR (Fig. 3B). However, 
intimal thickening was markedly reduced with some evi-
dence of endothelial denudation (Fig. 3B, inset). It must be 
emphasized that these morphological aberrations were less 
prominent than those observed after a single treatment with 
CTLA4-Ig and MR-l (Fig. 3A), which suggests that perhaps a 
relatively longer blockade of costimulatory pathways may be 
required to completely abrogate the development of CR. 
To test the latter tenet, we proceeded to contemporane-
ously block signaling through the CD281B7 and CD40/CD40L 
pathways by administering 10 consecutive doses ofCTLA4-Ig 
and anti-gp39 (Fig. I, group H). Interestingly, the majority of 
these aortic allografts obtained 30 days after transplantation 
retained normal morphology (Fig. 3, C, D, and E) indistin-
guishable from that of native aortas (Fig. 2A). This observa-
tion was reminiscent of our previously published data in 
which prior induction of liver-induced, donor-specific toler-
ance also abrogated the development of CR (12). 
Taken together, these data provide unequivocal evidence 
for the role for costimulatory molecules in the pathogenesis of 
posttransplant arteriosclerosis. Furthermore, these data also 
suggest that mitigation of acute cellular events by transient 
blockage of signaling through the costimulatory pathway 
may not provide optimal protection against the development 
of CR, necessitating a more stable interruption of signaling 
between antigen-presenting cells and alloreactive T cells. 
Refmement of this approach for its ultimate clinical applica-
tion for either prevention or reversal/mitigation of estab-
lished CR is the objective toward which all future endeavors 
have converged. 
animals (B and Bb inset); staining with Verhoeff-van Gieson's stain showed unimpaired internal elastic membrane (Bat Intimal thickening 
with disruption of internal elastic membrane was evident in untreated C3H recipients of B 10 AO stained with Verhoeff-van Gieson's stain 
(C). The intimal thickening was largely due to proliferation of a-smA + cells (C, insetl. The treatment of aortic allograft; recipients with 
irrelevant isotype-matched mAb did not mitigate the changes characteristic of CR, as were evident in Verhoeff-van Gieson-stained sections 
(0). Similarly, Verhoeff-van Gieson-stained sections of the aortas obtained from animals treated with either single (El or multiple (10) doses 
(F) of CTLA4-Ig (200 J.Lgidose i.p.) showed no amelioration of posttransplant arteriopathy. This observation was also made after treatment 
of recipients with three doses of MR-l, as depicted in Verhoeff-van Gieson-stained sections of aortic allografts (G). Original magnification: 
x 100. Insets: Aa and Ba, X400; Ab, Bb, and C, x 1000. 
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FIGURE 3. Microscopic examination of AO obtained at day 30 after transplantation from BlO--+C3H recipients in which signaling through 
both the CD281B7 and CD40/gp39 pathways was concurrently blocked. Unlike discrete blockage of costimulatory pathways, combined 
simultaneous treatment with a single dose of both CTLA4-Ig and MR-l resulted in marked reduction ofintimal thickening (A; Verhoeff-van 
Gieson's stain), which was patchy and eccentric (A, inset, hematoxylin and eosin). Further amelioration in changes distinctive of CR were 
evident after three doses of CTLA4-Ig and MR-l (8; Verhoeff-van Gieson's stain); nevertheless, minimal endothelial denudation (8, inset; 
hematoxylin and eosin) was discernible. It is noteworthy that in the majority of the animals, complete abrogation ofCR was observed after 
treatment with 10 doses of CTLA4-Ig and MR-l, as delineated in hematoxylin and eosin (C); Verhoeff-van Gieson (0)- and a-smA + 
(E )-stained sections of allogeneic aortas harvested on day 30 after transplantation. Original magnification: A and B, x 100; C, x 400; D and 
E, x200; insets, x400. 
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PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH 
DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS 
IN RENAL TRANSPLANT RECIPIENTS1,2t 
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Background. Treatment with prophylactic oral acy-
clovir, intravenous ganciclovir, or immunoglobulins 
to prevent cytomegalovirus (CMV) infection and dis-
ease in renal transplantation is associated with vari-
able efficacy and significant expense. We studied con-
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trol of CMV in renal transplant recipients using either 
prophylactic oral ganciclovir or deferred therapy with 
intensive monitoring with polymerase chain reaction 
(PCR) analysis. 
Methods. Forty-two recipients were followed for 6 
months after transplantation. Ganciclovir (1000 mg 
p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) 
was begun at transplantation and continued for 12 
weeks. PCR for CMV was performed on buffy-coat 
specimens every week for 15 weeks and at months 5 
and 6. 
Results_ No patients in the ganciclovir group, com· 
pared with 14 of 23 patients (61%) in the deferred-
therapy group (P<O.OOOl), developed CMV disease 
during the first 12 weeks. In the ganciclovir group, 4 of 
19 patients (21%) subsequently experienced 5 epi-
sodes, whereas 14 patients in the deferred-therapy 
group experienced 18 episodes (P=0.013 for subjects 
and P=0.026 for episodes). The time to disease was 
also delayed in the ganciclovir group compared with 
the deferred-therapy group (133±17 days vs. 51±7 
days; P<0.OOO1). Oral ganciclovir also prevented CMV 
viremia during prophylaxis (2119 patients [11%J vs. 
23123 patients [1000/0]). Time to CMV viremia was de-
